TQG 203
Alternative Names: Recombinant human coagulation factor VII; Recombinant human coagulation factor VIIa; TQG-203Latest Information Update: 12 Aug 2022
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIIa stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia A; Haemophilia B
Most Recent Events
- 28 Apr 2022 Phase-III clinical trials in Haemophilia A (In adults) in China (IV) (NCT05487976)
- 28 Apr 2022 Phase-III clinical trials in Haemophilia B (In adults) in China (IV) (NCT05487976)
- 01 Dec 2020 Phase-I clinical trials in Haemophilia A (In adults) in China (IV) (NCT04768699)